The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the MIRA Pharmaceuticals, Inc. Common Stock stock forecast from 0 analysts, the average analyst target price for MIRA Pharmaceuticals, Inc. Common Stock is not available over the next 12 months. MIRA Pharmaceuticals, Inc. Common Stock’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of MIRA Pharmaceuticals, Inc. Common Stock is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, MIRA Pharmaceuticals, Inc. Common Stock’s stock price was USD 1.55. MIRA Pharmaceuticals, Inc. Common Stock’s stock price has changed by -19.69% over the past week, -32.02% over the past month and -74.34% over the last year.
No recent analyst target price found for MIRA Pharmaceuticals, Inc. Common Stock
No recent average analyst rating found for MIRA Pharmaceuticals, Inc. Common Stock
Company Overview MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. Read Less
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pen...Read More
Frequently Asked Questions About MIRA Pharmaceuticals, Inc. Common Stock (MIRA) Stock
Stock Target Advisor's fundamental analysis for MIRA Pharmaceuticals, Inc. Common Stock's stock is Bearish.
Unfortunately we do not have enough data on MIRA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on MIRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on MIRA's stock to indicate if its overvalued.
The last closing price of MIRA's stock was USD 1.55.
The most recent market capitalization for MIRA is USD 0.03B.
Unfortunately we do not have enough analyst data on MIRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MIRA Pharmaceuticals, Inc. Common Stock's stock.
As per our most recent records MIRA Pharmaceuticals, Inc. Common Stock has 0 Employees.
MIRA Pharmaceuticals, Inc. Common Stock's registered address is 1200 Brickell Avenue, Miami, FL, United States, 32183.
You can get more information about it from MIRA Pharmaceuticals, Inc. Common Stock's website at https://mirapharmaceuticals.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About MIRA Pharmaceuticals, Inc. Common Stock (MIRA) Stock
Stock Target Advisor's fundamental analysis for MIRA Pharmaceuticals, Inc. Common Stock's stock is Bearish.
Unfortunately we do not have enough data on MIRA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on MIRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on MIRA's stock to indicate if its overvalued.
The last closing price of MIRA's stock was USD 1.55.
The most recent market capitalization for MIRA is USD 0.03B.
Unfortunately we do not have enough analyst data on MIRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MIRA Pharmaceuticals, Inc. Common Stock's stock.
As per our most recent records MIRA Pharmaceuticals, Inc. Common Stock has 0 Employees.
MIRA Pharmaceuticals, Inc. Common Stock's registered address is 1200 Brickell Avenue, Miami, FL, United States, 32183.
You can get more information about it from MIRA Pharmaceuticals, Inc. Common Stock's website at https://mirapharmaceuticals.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MIRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
